Morgan Stanley’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-242,262
| Closed | -$8.11M | – | 8571 |
|
|
2026
Q1 | $8.11M | Sell |
242,262
-45,377
| -16% | -$1.78M | ﹤0.01% | 3745 |
|
|
2025
Q4 | $13.3M | Buy |
287,639
+121,794
| +73% | +$6.68M | ﹤0.01% | 3339 |
|
|
2025
Q3 | $11.2M | Sell |
165,845
-274,209
| -62% | -$20.3M | ﹤0.01% | 3449 |
|
|
2025
Q2 | $36.9M | Buy |
440,054
+227,695
| +107% | +$17M | ﹤0.01% | 2201 |
|
|
2025
Q1 | $15.2M | Buy |
212,359
+2,122
| +1% | +$103K | ﹤0.01% | 2968 |
|
|
2024
Q4 | $9.45M | Buy |
210,237
+136,256
| +184% | +$7.06M | ﹤0.01% | 3457 |
|
|
2024
Q3 | $3.74M | Sell |
73,981
-18,996
| -20% | -$909K | ﹤0.01% | 4189 |
|
|
2024
Q2 | $3.79M | Sell |
92,977
-11,026
| -11% | -$467K | ﹤0.01% | 4112 |
|
|
2024
Q1 | $4.45M | Buy |
104,003
+2,629
| +3% | +$119K | ﹤0.01% | 4005 |
|
|
2023
Q4 | $4.08M | Buy |
101,374
+68,274
| +206% | +$1.94M | ﹤0.01% | 4495 |
|
|
2023
Q3 | $977K | Buy |
+33,100
| New | +$200K | ﹤0.01% | 4815 |
|
|
2023
Q1 | – | Sell |
-14
| Closed | -$28 | – | 7818 |
|
|
2022
Q4 | $28 | Sell |
14
-635
| -98% | -$790 | ﹤0.01% | 7753 |
|
|
2022
Q3 | $1K | Buy |
+649
| New | +$1.58K | ﹤0.01% | 7600 |
|
|
2022
Q2 | – | Sell |
-3
| Closed | – | – | 7949 |
|
|
2022
Q1 | $0 | Sell |
3
-18
| -86% | -$93 | ﹤0.01% | 8100 |
|
|
2021
Q4 | $0 | Sell |
21
-19
| -48% | -$199 | ﹤0.01% | 8096 |
|
|
2021
Q3 | $0 | Sell |
40
-670
| -94% | -$9.34K | ﹤0.01% | 8012 |
|
|
2021
Q2 | $12K | Buy |
710
+688
| +3,127% | +$11.6K | ﹤0.01% | 7185 |
|
|
2021
Q1 | $0 | Sell |
22
-2,920
| -99% | -$94.1K | ﹤0.01% | 7549 |
|
|
2020
Q4 | $85K | Buy |
2,942
+2,367
| +412% | +$68.3K | ﹤0.01% | 5977 |
|
|
2020
Q3 | $22K | Sell |
575
-464
| -45% | -$13.6K | ﹤0.01% | 6032 |
|
|
2020
Q2 | $35K | Buy |
1,039
+1,012
| +3,748% | +$43.9K | ﹤0.01% | 5811 |
|
|
2020
Q1 | $1K | Buy |
27
+22
| +440% | +$936 | ﹤0.01% | 6483 |
|
|
2019
Q4 | $0 | Sell |
5
-32
| -86% | -$819 | ﹤0.01% | 6751 |
|
|
2019
Q3 | $1K | Hold |
37
| – | – | ﹤0.01% | 6570 |
|
|
2019
Q2 | $2K | Sell |
37
-19
| -34% | -$657 | ﹤0.01% | 6471 |
|
|
2019
Q1 | $2K | Buy |
56
+55
| +5,500% | +$1.46K | ﹤0.01% | 6464 |
|
|
2018
Q4 | $0 | Buy |
+1
| New | +$29 | ﹤0.01% | 6722 |
|
|
2018
Q1 | – | Sell |
-10
| Closed | – | – | 6689 |
|
|
2017
Q4 | $0 | Sell |
10
-4
| -29% | -$115 | ﹤0.01% | 6639 |
|
|
2017
Q3 | $1K | Sell |
14
-5
| -26% | -$197 | ﹤0.01% | 6465 |
|
|
2017
Q2 | $1K | Hold |
19
| – | – | ﹤0.01% | 6519 |
|
|
2017
Q1 | $1K | Buy |
+19
| New | +$1.12K | ﹤0.01% | 6507 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6641 |
|
|
2016
Q1 | – | Sell |
-126
| Closed | -$12.3K | – | 6701 |
|
|
2015
Q4 | $18K | Sell |
126
-526
| -81% | -$77K | ﹤0.01% | 6072 |
|
|
2015
Q3 | $103K | Buy |
+652
| New | +$118K | ﹤0.01% | 5411 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6738 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6642 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6655 |
|
Morgan Stanley's SLNO Position: Q2 2026 in Review
Morgan Stanley sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 242,262 shares — an estimated $8.11M sold.
Morgan Stanley first reported a position in SLNO in Q3 2015 and held it in 33 quarters. The position peaked at $36.9M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Morgan Stanley reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Morgan Stanley sold 242,262 Soleno Therapeutics shares in Q2 2026, an estimated $8.11M.
- Morgan Stanley first reported a position in Soleno Therapeutics in Q3 2015 and held it in 33 quarters.
- Morgan Stanley's Soleno Therapeutics position peaked at $36.9M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.